Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Richard G EversonYuuri HashimotoJacob L FreemanTiffany R HodgesJason HuseShouhao ZhouJoanne XiuDavid SpetzlerNader SanaiLyndon KimSantosh KesariAndrew BrennerFranco De MonteAmy B HeimbergerShaan M Raza

Published in: Journal of neuro-oncology (2018)

If predicated on tumor expression, our data suggest that therapeutics directed toward NF2 and TOP2A could be considered for most meningioma patients.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
poor prognosis
prognostic factors
oxidative stress
emergency department
randomized controlled trial
optic nerve
machine learning
lps induced
single cell
study protocol
binding protein
inflammatory response
pi k akt
phase iii